UK Public Health Rapid Support Team deploys to Sierra Leone to help prevent disease outbreaksMonday 21 August 2017
New global estimates illustrate vast impact of two most common chronic respiratory diseases – expert commentFriday 18 August 2017
Led by researchers from the Institute of Health Metrics and Evaluation, University of Washington, the
99DOTS: A low-cost real-time technology for remote adherence monitoring for TB treatment using mobile phones
Wed 23 Aug 2017
Keppel Street, London, United Kingdom
Lilongwe Alumni Networking Event August 2017
Thu 24 Aug 2017
Sunbird Capital Hotel, Chilembwe Road, Lilongwe, Malawi
Year 8 schoolgirls in the UK (12-13 years old) receive two doses each of a vaccine against human papillomavirus (HPV), a virus that causes cervical cancer as well as genital warts and a number of other unpleasant cancers. Until 2013, they received three doses of the vaccine each.
I was disheartened to learn last week that the US Federal Drug Administration approved flibanserin for treatment of low female sexual desire. The decision was claimed as a victory for women. But as a researcher working in sexual dysfunction and interested in the medicalisation of sex, the victory tasted a little bitter.
Recent positive results from the Guinea Ebola vaccine trial, which suggested a vaccine could provide high protection against the virus, were welcome news. However, it’s also essential that we continue to carry out research to ensure Ebola patients are receiving appropriate care and effective treatment.